What is the current Exelixis market capitalization?
The current market capitalization of Exelixis is 7.09 B USD.
Exelixis Market capitalization 2024
Exelixis Market capitalization
7.09 B USD
Ticker
EXEL
ISIN
US30161Q1040
WKN
936718
In 2024, Exelixis's market cap stood at 7.09 B USD, a 11.44% increase from the 6.36 B USD market cap in the previous year.
The Exelixis Market capitalization history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) | NET INCOME (undefined USD) |
|---|---|---|---|
| 2029e | 2.73 | 64,36 | 921.8 |
| 2028e | 2.73 | 64,38 | 850.08 |
| 2027e | 2.59 | 67,89 | 743.77 |
| 2026e | 2.33 | 75,37 | 557.63 |
| 2025e | 2.1 | 83,58 | 438.41 |
| 2024e | 1.91 | 91,83 | 334.55 |
| 2023 | 1.83 | 96,04 | 207.77 |
| 2022 | 1.61 | 96,41 | 182.3 |
| 2021 | 1.44 | 96,31 | 231.1 |
| 2020 | 0.99 | 96,33 | 111.8 |
| 2019 | 0.97 | 96,58 | 321 |
| 2018 | 0.85 | 96,92 | 690.1 |
| 2017 | 0.45 | 96,66 | 154.2 |
| 2016 | 0.19 | 96,55 | -70.2 |
| 2015 | 0.04 | 89,52 | -161.7 |
| 2014 | 0.03 | 92,03 | -261.3 |
| 2013 | 0.03 | 96,49 | -244.8 |
| 2012 | 0.05 | 100,00 | -147.6 |
| 2011 | 0.29 | 606,93 | 75.7 |
| 2010 | 0.19 | 950,09 | -92.3 |
| 2009 | 0.15 | 1157,88 | -135.2 |
| 2008 | 0.12 | 1490,81 | -162.9 |
| 2007 | 0.11 | 1548,60 | -86.4 |
| 2006 | 0.1 | 1780,81 | -101.5 |
| 2005 | 0.08 | 2312,71 | -84.4 |
| 2004 | 0.05 | 3322,61 | -137.2 |
Exelixis Aktienanalyse
What does Exelixis do?
Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring Exelixis's Market Capitalization
Exelixis's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of Exelixis's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
Exelixis's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in Exelixis’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about Exelixis stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Exelixis.
How has the market capitalization of Exelixis developed in recent years?
The market capitalization of Exelixis has increased/decreased by 11.44% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of Exelixis?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of Exelixis?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of Exelixis have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does Exelixis pay?
Over the past 12 months, Exelixis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Exelixis is expected to pay a dividend of 0 USD.
What is the dividend yield of Exelixis?
The current dividend yield of Exelixis is .
When does Exelixis pay dividends?
Exelixis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Exelixis?
Exelixis paid dividends every year for the past 0 years.
What is the dividend of Exelixis?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Exelixis located?
Exelixis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Exelixis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Exelixis from 7/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/11/2024.
When did Exelixis pay the last dividend?
The last dividend was paid out on 7/11/2024.
What was the dividend of Exelixis in the year 2023?
In the year 2023, Exelixis distributed 0 USD as dividends.
In which currency does Exelixis pay out the dividend?
The dividends of Exelixis are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Exelixis
Our stock analysis for Exelixis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Exelixis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
